• MeSH
• Acromegaly complications   MeSH
• Alkaptonuria complications   MeSH
• beta-Thalassemia complications   MeSH
• Diagnosis, Differential MeSH
• Gaucher Disease complications   MeSH
• Glucocorticoids administration & dosage   MeSH
• Hemochromatosis complications   MeSH
• Hemophilia A complications   MeSH
• Hemoglobinopathies classification   complications   MeSH
• Hepatolenticular Degeneration complications   MeSH
• Hyperlipidemias drug therapy   classification   complications   MeSH
• Hypolipidemic Agents administration & dosage   MeSH
• Comorbidity MeSH
• Diabetes Complications MeSH
• Hematologic Diseases complications   MeSH
• Humans MeSH
• Neoplasms complications   MeSH
• Endocrine System Diseases classification   complications   MeSH
• Joint Diseases diagnostic imaging   etiology   drug therapy   classification   MeSH
• Thyroid Diseases complications   MeSH
• Muscular Diseases complications   MeSH
• Paraneoplastic Syndromes diagnosis   MeSH
• Rheumatic Diseases * diagnostic imaging   etiology   drug therapy   classification   MeSH
• Sphingolipidoses classification   complications   MeSH
• Anemia, Sickle Cell complications   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Review MeSH

• MeSH
• Nutrition Assessment MeSH
• Hyperlipidemias etiology   classification   pathology   MeSH
• Communicable Diseases complications   MeSH
• Humans MeSH
• Endocrine System Diseases complications   MeSH
• Liver Diseases complications   MeSH
• Kidney Diseases complications   MeSH
• Bile Duct Diseases complications   MeSH
• Nutrition Disorders complications   MeSH
• Xenobiotics MeSH
• Check Tag
• Humans MeSH

U nemocných s diabetes mellitus je velmi vysoký výskyt dyslipidemie. Je nutno rozlišovat mezi sekundární dyslipidemií způsobenou neuspokojivou kompenzací diabetu a dyslipidemií jako samostatným onemocněním sdruženým s diabetes mellitus. Typickým nálezem je kombinovaná hyperlipoproteinemie, časté je i snížení HDL-cholesterolu. Pravidlem bývá i zvýšený apolipoprotein B100 a zvýšená koncentrace malých LDL3. Cílové hodnoty krevních lipidů jsou stejné jako u nemocných v sekundární prevenci kardiovaskulárních onemocnění. Základem léčby je dobrá kompenzace diabetu, úprava tělesné hmotnosti, změna stravovacích návyků a pravidelná fyzická aktivita. Nevedou-li tyto změny k úpravě krevních lipidů, jsou indikována hypolipidemika. Při jejich výběru je třeba zohlednit typ dyslipidemie. Hlavním cílem je dosažení cílové koncentrace LDL-cholesterolu (nebo non HDL-cholesterolu). U velké části nemocných s diabetes mellitus je indikována kombinovaná léčba statinu s fibrátem.

The prevalence of lipid disorders in diabetic patients is very high. It is necessary to differentiate between secondary dyslipidemia caused by insufficient diabetes compensation and dyslipidemia as a separate disorder associated with diabetes mellitus. The combined hyperlipidemia is a typical finding, frequently associated with a decrease of HDL-cholesterol. Frequently we encounter also an increase of apolipoprotein B100 and increased concentration of small LDL3. Target blood levels of lipids are the same as in patients in secondary prevention of cardiovascular diseases. A good control of diabetes, optimizing of body weight, dietary changes and regular physical activity are essential in the treatment. If these measures do not lead to improvement in lipid profile, therapy with hypolipidemics is indicated. The choice of medications should reflect the type of dyslipidemia. Reaching of target levels of LDL-cholesterol or non HDL-cholesterol are the principal goal of treatment. A combined therapy with a statin and a fibrate is indicated in a large number of patients.

• MeSH
• Diabetes Mellitus MeSH
• Hyperlipidemias diagnosis   drug therapy   classification   MeSH
• Humans MeSH
• Lipoproteins, HDL analysis   blood   MeSH
• Lipoproteins, LDL analysis   blood   MeSH
• Review Literature as Topic MeSH
• Health Behavior MeSH
• Check Tag
• Humans MeSH

• MeSH
• Azetidines administration & dosage   contraindications   therapeutic use   MeSH
• Ezetimibe MeSH
• Hyperlipidemias drug therapy   classification   complications   MeSH
• Cardiovascular Diseases epidemiology   etiology   therapy   MeSH
• Humans MeSH
• Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacokinetics   classification   MeSH
• Kidney Transplantation classification   contraindications   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Comparative Study MeSH

• MeSH
• Azetidines administration & dosage   contraindications   therapeutic use   MeSH
• Ezetimibe MeSH
• Hyperlipidemias drug therapy   classification   complications   MeSH
• Immunosuppressive Agents pharmacokinetics   adverse effects   therapeutic use   MeSH
• Cardiovascular Diseases epidemiology   etiology   therapy   MeSH
• Humans MeSH
• Kidney Transplantation classification   contraindications   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Comparative Study MeSH

• MeSH
• Arteriosclerosis etiology   metabolism   therapy   MeSH
• Hyperlipidemias classification   blood   metabolism   MeSH
• Hypolipidemic Agents pharmacology   classification   therapeutic use   MeSH
• Cardiovascular Diseases etiology   complications   physiopathology   MeSH
• Humans MeSH
• Metabolic Syndrome physiopathology   prevention & control   therapy   MeSH
• Check Tag
• Humans MeSH

• MeSH
• Research Support as Topic MeSH
• Hyperlipidemias classification   complications   MeSH
• Myocardial Infarction etiology   genetics   therapy   MeSH
• Coronary Disease etiology   complications   therapy   MeSH
• Coronary Thrombosis genetics   MeSH
• Middle Aged MeSH
• Humans MeSH
• Thrombophilia classification   complications   MeSH
• Age Factors MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH

• MeSH
• Anticholesteremic Agents administration & dosage   pharmacology   MeSH
• Azetidines administration & dosage   pharmacology   MeSH
• Diabetes Mellitus etiology   MeSH
• Hyperlipidemias diagnosis   drug therapy   classification   MeSH
• Hypolipidemic Agents administration & dosage   pharmacology   MeSH
• Clofibrate analogs & derivatives   administration & dosage   pharmacology   MeSH
• Drug Therapy, Combination MeSH
• Humans MeSH
• Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage   pharmacology   MeSH
• Check Tag
• Humans MeSH

Význam dyslipidemií je hlavně v tom, že zvyšují kardiovaskulární riziko. Patři mezi hlavní rizikové kardiovaskulární faktory, a to mezi faktory ovlivnitelné. Jejich hlavní rozdělení je na primární (polygenni hypercholesterolémie, familiární hypercholesterolémie, familiární defekt apolipoproteinu B 100, dysbetalipoproteinémie, e, familiární kombinovaná hyperlipidemie amiliarni hyperchylomikronemie, familiární hypertríglycendemie) a i na sekundární. Sekundární dyslipidemie se mohou objevovat při různých interních chorobách. Při záchytu dyslipidemie u pacienta je důležité vyloučit sekundární hyperlipoproteinémii a nemocnému provést biochemický screening a fyzikální vyšetření.

• MeSH
• Cholesterol pharmacology   classification   metabolism   MeSH
• Hyperlipidemia, Familial Combined drug therapy   genetics   metabolism   MeSH
• Hyperlipidemias drug therapy   classification   complications   MeSH
• Cardiovascular Diseases etiology   drug therapy   complications   MeSH
• Humans MeSH
• Risk Factors MeSH
• Check Tag
• Humans MeSH

• MeSH
• Diabetes Mellitus, Type 2 diagnosis   metabolism   physiopathology   MeSH
• Hyperlipidemias etiology   classification   therapy   MeSH
• Coronary Disease etiology   MeSH
• Humans MeSH
• Metabolic Syndrome classification   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Review MeSH